非典型股骨骨折患者的药物治疗:欧洲钙化组织学会的系统综述与推荐
欧洲钙化组织学会系统综述评估特立帕肽、雷洛昔芬和地舒单抗对非典型股骨骨折愈合及发生的影响。共检索910篇文献、复习67篇论文,无随机对照试验。观察性数据提示特立帕肽可能使手术治疗的非典型股骨骨折愈合更快,但尚无循证指征,基于专家意见提出治疗推荐。
要点
- 特立帕肽治疗非典型股骨骨折:保守治疗的不完全骨折6个月内影像学愈合13/30(43%),手术治疗的不完全骨折9/10(90%),完全骨折44/58(75%)。
- 30例未手术的不完全骨折中9例(30%)12个月后未愈合,4例(13%)在特立帕肽治疗期间进展为完全骨折;8例患者在特立帕肽治疗期间或之后出现新发非典型股骨骨折。
- 地舒单抗相关非典型股骨骨折报告22例,其中11例为骨转移治疗患者、8例无双膦酸盐暴露史;骨折后使用地舒单抗与1例复发性不完全骨折和2例对侧完全骨折相关。
核心结论
- 非典型股骨骨折患者使用特立帕肽尚无循证指征,除非为降低典型脆性骨折风险;观察性数据提示特立帕肽可能使手术治疗的非典型股骨骨折愈合更快。
- 等待进一步证据期间,基于专家意见制定非典型股骨骨折后的治疗推荐。
研究设计与样本
- 系统综述,检索910篇文献,复习67篇论文,包括31篇病例报告、9项回顾性研究和3项关于特立帕肽的前瞻性研究;无随机对照试验。
主要发现
- 特立帕肽治疗非典型股骨骨折的骨折愈合汇总数据(n=98例非典型股骨骨折):保守治疗的不完全骨折6个月内影像学愈合13/30(43%),手术治疗的不完全骨折9/10(90%),完全骨折44/58(75%)。
- 30例未手术的不完全骨折中9例(30%)12个月后未愈合,4例(13%)在特立帕肽治疗期间进展为完全骨折;8例患者在特立帕肽治疗期间或之后出现新发非典型股骨骨折。
- 地舒单抗相关非典型股骨骨折报告22例,其中11例为骨转移治疗患者、8例无双膦酸盐暴露史;骨折后使用地舒单抗与1例复发性不完全骨折和2例对侧完全骨折相关。
- 8例患者在非典型股骨骨折发生前使用过雷洛昔芬,其中1例无双膦酸盐暴露史。
关键数值与推荐
- 非典型股骨骨折患者使用特立帕肽尚无循证指征,除非为降低典型脆性骨折风险(原文未给出推荐等级,基于专家意见)。
临床怎么用
- 原文未据此给出具体临床推荐,仅基于专家意见提出非典型股骨骨折后的治疗推荐。
局限性
- 无随机对照试验。
- 观察性数据提示特立帕肽可能使手术治疗的非典型股骨骨折愈合更快,但需等待进一步证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Atypical femur fractures (AFFs) are serious adverse events associated with bisphosphonates and often show poor healing. EVIDENCE ACQUISITION: We performed a systematic review to evaluate effects of teriparatide, raloxifene, and denosumab on healing and occurrence of AFF. EVIDENCE SYNTHESIS: We retrieved 910 references and reviewed 67 papers, including 31 case reports, 9 retrospective and 3 prospective studies on teriparatide. There were no RCTs. We pooled data on fracture union (n = 98 AFFs on teriparatide) and found that radiological healing occurred within 6 months of teriparatide in 13 of 30 (43%) conservatively managed incomplete AFFs, 9 of 10 (90%) incomplete AFFs with surgical intervention, and 44 of 58 (75%) complete AFFs. In 9 of 30 (30%) nonoperated incomplete AFFs, no union was achieved after 12 months and 4 (13%) fractures became complete on teriparatide. Eight patients had new AFFs during or after teriparatide. AFF on denosumab was reported in 22 patients, including 11 patients treated for bone metastases and 8 without bisphosphonate exposure. Denosumab after AFF was associated with recurrent incomplete AFFs in 1 patient and 2 patients of contralateral complete AFF. Eight patients had used raloxifene before AFF occurred, including 1 bisphosphonate-naïve patient. CONCLUSIONS: There is no evidence-based indication in patients with AFF for teriparatide apart from reducing the risk of typical fragility fractures, although observational data suggest that teriparatide might result in faster healing of surgically treated AFFs. Awaiting further evidence, we formulate recommendations for treatment after an AFF based on expert opinion.
引用
- van de Laarschot DM, McKenna MJ, Abrahamsen B, et al. Medical Management of Patients After Atypical Femur Fractures: a Systematic Review and Recommendations From the European Calcified Tissue Society. J Clin Endocrinol Metab. 2020. PMID: 31867670. doi:10.1210/clinem/dgz295
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。